Related Experiment Video

Updated: May 7, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Therapeutic human monoclonal antibodies against cancer

Jamie Jarboe1, Anumeha Gupta, M W Saif

  • 1Tufts cancer center, Tufts university school of medicine, Boston, MA, USA.

Methods in Molecular Biology (Clifton, N.J.)
|September 17, 2013
PubMed

Insights

Monoclonal antibodies are FDA-approved for various diseases, including cancers and autoimmune conditions. Several top-grossing antibodies are utilized in oncology for treating malignancies.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Over 30 monoclonal antibodies have received FDA approval for diverse medical conditions.
  • These therapeutic antibodies encompass murine, chimeric, and fully humanized formats.
  • Monoclonal antibodies are integral to modern medicine, particularly in treating malignancies.

Purpose of the Study:

  • To highlight the prevalence and significance of monoclonal antibodies in clinical practice.
  • To emphasize the role of monoclonal antibodies in cancer therapy.
  • To provide an overview of the types and applications of approved monoclonal antibodies.

Main Methods:

  • Review of FDA-approved monoclonal antibody landscape.
  • Analysis of antibody types (murine, chimeric, humanized).
  • Examination of monoclonal antibody applications in oncology.

Main Results:

  • A substantial number of monoclonal antibodies are approved for treating malignancies, autoimmune diseases, and macular degeneration.
  • Key oncology drugs like bevacizumab, trastuzumab, and rituximab are monoclonal antibodies.
  • Three of the top five highest-grossing antibodies are used in cancer treatment.

Conclusions:

  • Monoclonal antibodies represent a significant class of therapeutics with broad clinical applications.
  • Their efficacy in treating malignancies underscores their importance in oncology.
  • The continued development and approval of monoclonal antibodies are vital for advancing patient care across various diseases.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...